Biogen’s Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP’s Positive Opinion to Use During Pregnancy and Breastfeeding

 Biogen’s Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP’s Positive Opinion to Use During Pregnancy and Breastfeeding

Biogen’s Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP’s Positive Opinion to Use During Pregnancy and Breastfeeding

Shots:

  • The CHMP recommended an update to MAA of approved interferon beta treatments (Plegridy & Avonex) to remove pregnancy contraindications and allow them to use during pregnancy and breastfeeding in women with relapsing multiple sclerosis
  • The CHMP positive opinion is based on 1,000+ real-world pregnancy outcomes demonstrating no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during the first trimester
  • Plegridy (q2w) is subcutaneous pegylated interferon indicated in RRMS while AVONEX is one of the most prescribed treatments for relapsing forms of MS, currently approved in 90+ countries

Click here to­ read full press release/ article | Ref: Biogen | Image: The Business Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post